{"id":"NCT00457002","sponsor":"Bristol-Myers Squibb","briefTitle":"Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness","officialTitle":"A Phase 3 Randomized, Double-Blind, Parallel-group, Multi-center Study of the Safety and Efficacy of Apixaban for Prophylaxis of Venous Thromboembolism in Acutely Ill Medical Subjects During and Following Hospitalization.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-06","primaryCompletion":"2011-05","completion":"2011-05","firstPosted":"2007-04-05","resultsPosted":"2014-05-20","lastUpdate":"2015-12-08"},"enrollment":6758,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Venous Thrombosis","Pulmonary Embolism"],"interventions":[{"type":"DRUG","name":"Apixaban","otherNames":["BMS-562247"]},{"type":"DRUG","name":"Enoxaparin","otherNames":[]}],"arms":[{"label":"Arm 1","type":"EXPERIMENTAL"},{"label":"Arm 2","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to learn if apixaban can prevent blood clots in the leg (deep vein thrombosis \\[DVT\\]) and lung (pulmonary embolism \\[PE\\]) that sometimes occur within patients hospitalized for acute medical illness, and to learn how apixaban compares to enoxaparin (Lovenox®) for preventing these clots. The safety of apixaban will also be studied.","primaryOutcome":{"measure":"Incidence of Composite of Adjudicated Total Venous Thromboembolism (VTE) and VTE-related Death During the Intended Treatment Period - Primary Efficacy Population","timeFrame":"Intended Treatment Period","effectByArm":[{"arm":"Apixaban 2.5 mg","deltaMin":2.71,"sd":null},{"arm":"Enoxaparin 40 mg","deltaMin":3.06,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.4364"},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":4},"locations":{"siteCount":296,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","Colombia","Czechia","Denmark","France","Germany","Hong Kong","Hungary","India","Israel","Italy","Malaysia","Mexico","Netherlands","Norway","Peru","Philippines","Poland","Russia","Singapore","South Africa","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["28762617","28617144","22863355","22077144"],"seeAlso":["http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"]},"adverseEventsSummary":{"seriousAny":{"events":611,"n":3184},"commonTop":[]}}